Brian G. Till
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Brian G. Till

Oncology
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Experienced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
The Association Of University Physicians
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Till is an Oncologist in Seattle, Washington. Dr. Till is rated as an Experienced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Follicular Lymphoma. Dr. Till is currently accepting new patients.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Castilian
Filipino
French
Mandarin
Romanian
Russian
Spanish
Vietnamese
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
View 1 Less Clinical Trial

92 Total Publications

Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
Journal: British journal of haematology
Published: May 27, 2025
Similar Doctors
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Francis M. Senecal
Hematology Oncology | Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Francis M. Senecal
Hematology Oncology | Hematology | Oncology

Northwest Medical Specialties PLLC

11511 Canterwood Blvd, Suite 45, 
Gig Harbor, WA 
 (22.5 miles away)
253-428-8700
Languages Spoken:
English, Castilian, Dutch, Konkani, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Senecal is a Hematologist Oncology specialist and a Hematologist in Gig Harbor, Washington. Dr. Senecal is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Senecal is currently accepting new patients.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Stephen D. Smith
Hematology Oncology | Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Stephen D. Smith
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, Mandarin, Portuguese, Quechua, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Smith is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), Large-Cell Immunoblastic Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). Dr. Smith is currently accepting new patients.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Ning Dong
Hematology Oncology | Hematology | Oncology
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Dr. Ning Dong
Hematology Oncology | Hematology | Oncology

Swedish Health Services

751 Ne Blakely Dr, Suite 1090, 
Issaquah, WA 
 (15.6 miles away)
425-313-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ning Dong is a Hematologist Oncology specialist and a Hematologist in Issaquah, Washington. Dr. Dong is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Lymphadenectomy. Dr. Dong is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Till's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile